Roche Commercially Launches Axelios 1 Sequencer, Targets North America and Select Global Markets
After a year-long drumroll, Roche starts shipping the Axelios 1 sequencer commercially this week with an initial focus on North America, Europe, and Asia-Pacific.
Read the full articleYou might also wanna read
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engager
AI accelerates search for cancer therapeutics in Korea
Artificial intelligence (AI) has helped SK Telecom and SK Biopharmaceuticals identify promising early compounds for a targeted cancer therap
Celltrion's High-Margin Follow-On Products Expand Share in Europe
Celltrion's high-margin follow-on biosimilars are expanding their share across Europe, with Omlyclo reaching 16% and Vegzelma and Yuflyma ho
Bruker Acquires Disqver Metagenomic Sequencing Platform for Blood Infections
The deal with Germany's Noscendo adds the ability to screen for more than 11,000 microbes and parasites directly from blood samples.
Enterprise AI Profile: The Roche Group
The Roche Group and its subsidiaries are using AI to advance pharmaceutical R&D and healthcare diagnostics and treatment
STAT+: Roche drug sets new standard for KRAS-driven lung cancer
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Comments
Sign in to join the conversation.
No comments yet. Be the first.